Man Group
EIGR

Man Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Man Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-390
Closed -$104K – 2127
2021
Q1 		$104K Sell
390
-1,767
-82% -$557K ﹤0.01% 1798
2020
Q4 		$795K Sell
2,157
-365
-14% -$105K ﹤0.01% 1464
2020
Q3 		$616K Buy
2,522
+2,117
+523% +$659K ﹤0.01% 1496
2020
Q2 		$117K Buy
+405
New +$119K ﹤0.01% 1626

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Man Group's EIGR Position: Q2 2021 in Review

Man Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2021, closing a stake of 390 shares — an estimated $104K sold.

Man Group first reported a position in EIGR in Q2 2020 and held it in 4 quarters. The position peaked at $795K in Q4 2020. 90 funds tracked by Wall St. Rank hold EIGR as of Q2 2021.

  • Man Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Man Group sold 390 Eiger BioPharmaceuticals, Inc. shares in Q2 2021, an estimated $104K.
  • Man Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2020 and held it in 4 quarters.
  • Man Group's Eiger BioPharmaceuticals, Inc. position peaked at $795K in Q4 2020.
  • 90 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2021.

Based on Man Group's 13F filing for Q2 2021, filed 16 Aug 2021.